APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma
An 11-year-old spayed female Beagle presented with tenesmus and was identified with a rectal wall mass. Diagnostic imaging (abdominal ultrasound and computed tomography) localised the mass in the right rectal wall and documented no evidence of metastatic disease. Subsequently, the dog underwent surg...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Veterinary Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-7381/11/12/628 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846102449987780608 |
|---|---|
| author | Valentina Rinaldi Laura Bongiovanni Paolo Emidio Crisi Massimo Vignoli Renato Ennio Peli Stefano Masci Andrea Boari Riccardo Finotello |
| author_facet | Valentina Rinaldi Laura Bongiovanni Paolo Emidio Crisi Massimo Vignoli Renato Ennio Peli Stefano Masci Andrea Boari Riccardo Finotello |
| author_sort | Valentina Rinaldi |
| collection | DOAJ |
| description | An 11-year-old spayed female Beagle presented with tenesmus and was identified with a rectal wall mass. Diagnostic imaging (abdominal ultrasound and computed tomography) localised the mass in the right rectal wall and documented no evidence of metastatic disease. Subsequently, the dog underwent surgery for tumour excision. A histopathological diagnosis of melanoma was performed. To confirm the tumour histotype, immunohistochemistry was performed using anti-Melan A and anti-Ki67. Neoplastic cells exhibited focal Melan A immunoreactivity and widespread nuclear immunoreactivity for Ki67 with a Ki67 index of 27%. Adjuvant immunotherapy with APAVAC<sup>®</sup> was initiated. After APAVAC administration, no local or systemic acute adverse events were observed. Four pre- and post-contrast computed tomography (CT) studies were performed in an 18-month follow-up period every 4–5 months. Follow-up rectal palpation and conscious visualisation of the surgical site have also resulted in no macroscopic signs of tumour recurrence. The dog remains alive and with no clinical evidence of tumour recurrence and/or distant progression at the time of writing, therefore, surviving over 540 days from the diagnosis. |
| format | Article |
| id | doaj-art-bf1c277c51ed4de4b1c6930a7ad51411 |
| institution | Kabale University |
| issn | 2306-7381 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Veterinary Sciences |
| spelling | doaj-art-bf1c277c51ed4de4b1c6930a7ad514112024-12-27T14:58:36ZengMDPI AGVeterinary Sciences2306-73812024-12-01111262810.3390/vetsci11120628APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal MelanomaValentina Rinaldi0Laura Bongiovanni1Paolo Emidio Crisi2Massimo Vignoli3Renato Ennio Peli4Stefano Masci5Andrea Boari6Riccardo Finotello7Department of Veterinary Medicine, University of Teramo, 64100 Teramo, ItalyDepartment of Veterinary Medicine, University of Teramo, 64100 Teramo, ItalyDepartment of Veterinary Medicine, University of Teramo, 64100 Teramo, ItalyDepartment of Veterinary Medicine, University of Teramo, 64100 Teramo, ItalyDepartment of Veterinary Medicine, University of Teramo, 64100 Teramo, ItalyClinica Veterinaria Colli Innamorati, via Colli Innamorati 21, 65125 Pescara, ItalyDepartment of Veterinary Medicine, University of Teramo, 64100 Teramo, ItalyOspedale Veterinario I Portoni Rossi, Anicura Italy Holding, via Roma 51, 40069 Zola Predosa, ItalyAn 11-year-old spayed female Beagle presented with tenesmus and was identified with a rectal wall mass. Diagnostic imaging (abdominal ultrasound and computed tomography) localised the mass in the right rectal wall and documented no evidence of metastatic disease. Subsequently, the dog underwent surgery for tumour excision. A histopathological diagnosis of melanoma was performed. To confirm the tumour histotype, immunohistochemistry was performed using anti-Melan A and anti-Ki67. Neoplastic cells exhibited focal Melan A immunoreactivity and widespread nuclear immunoreactivity for Ki67 with a Ki67 index of 27%. Adjuvant immunotherapy with APAVAC<sup>®</sup> was initiated. After APAVAC administration, no local or systemic acute adverse events were observed. Four pre- and post-contrast computed tomography (CT) studies were performed in an 18-month follow-up period every 4–5 months. Follow-up rectal palpation and conscious visualisation of the surgical site have also resulted in no macroscopic signs of tumour recurrence. The dog remains alive and with no clinical evidence of tumour recurrence and/or distant progression at the time of writing, therefore, surviving over 540 days from the diagnosis.https://www.mdpi.com/2306-7381/11/12/628melanomadogimmunotherapytumouroncology |
| spellingShingle | Valentina Rinaldi Laura Bongiovanni Paolo Emidio Crisi Massimo Vignoli Renato Ennio Peli Stefano Masci Andrea Boari Riccardo Finotello APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma Veterinary Sciences melanoma dog immunotherapy tumour oncology |
| title | APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma |
| title_full | APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma |
| title_fullStr | APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma |
| title_full_unstemmed | APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma |
| title_short | APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma |
| title_sort | apavac immunotherapy for the adjuvant treatment of a canine mucosal melanoma |
| topic | melanoma dog immunotherapy tumour oncology |
| url | https://www.mdpi.com/2306-7381/11/12/628 |
| work_keys_str_mv | AT valentinarinaldi apavacimmunotherapyfortheadjuvanttreatmentofacaninemucosalmelanoma AT laurabongiovanni apavacimmunotherapyfortheadjuvanttreatmentofacaninemucosalmelanoma AT paoloemidiocrisi apavacimmunotherapyfortheadjuvanttreatmentofacaninemucosalmelanoma AT massimovignoli apavacimmunotherapyfortheadjuvanttreatmentofacaninemucosalmelanoma AT renatoenniopeli apavacimmunotherapyfortheadjuvanttreatmentofacaninemucosalmelanoma AT stefanomasci apavacimmunotherapyfortheadjuvanttreatmentofacaninemucosalmelanoma AT andreaboari apavacimmunotherapyfortheadjuvanttreatmentofacaninemucosalmelanoma AT riccardofinotello apavacimmunotherapyfortheadjuvanttreatmentofacaninemucosalmelanoma |